Corporate ActionJul 31, 2026, 09:19 AM
FibroBiologics Seeks Approval for 8.45M Share Issuance
AI Summary
FibroBiologics, Inc. is holding a Special Meeting on September 17, 2026, to seek stockholder approval for the issuance of up to 8,163,266 shares of common stock upon the exercise of outstanding warrants from a June 2026 Securities Purchase Agreement, and an additional 285,714 shares for placement agent warrants. This approval is required under Nasdaq Listing Rule 5635(d) because the potential issuance exceeds 20% of outstanding shares. The Board recommends approval, noting that failure to do so could result in liquidated damages and significant legal expenses, while approval could bring in approximately $6.26 million from warrant exercises.
Key Highlights
- Special Meeting of Stockholders scheduled for September 17, 2026, to approve share issuance.
- Approval sought for issuance of up to 8,163,266 common shares from Securities Purchase Agreement warrants.
- Approval also sought for issuance of up to 285,714 common shares from Placement Agent Warrants.
- Stockholder approval is required under Nasdaq Listing Rule 5635(d) due to the issuance size.
- Full exercise of warrants could generate approximately $6.26 million in gross proceeds for the company.
- Failure to approve could result in liquidated damages and ongoing legal expenses for the company.
- Pete O'Heeron, CEO, holds 125 Series C Preferred Shares with 13,000 votes each, totaling 20% of voting power.
- The record date for stockholders entitled to vote at the Special Meeting is July 20, 2026.
Price Impact
More from FBLG
More in Corporate Action